Literature DB >> 11331447

Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer.

C M Lennard1, A Patel, J Wilson, B Reinhardt, C Tuman, C Fenton, E Blair, G L Francis, R M Tuttle.   

Abstract

BACKGROUND: Vascular endothelial growth factor (VEGF) induces proliferation of endothelial cells, stimulates angiogenesis, and increases vascular permeability. Increased VEGF expression has been associated with poor clinical outcomes in many malignancies. Several recent reports have documented over expression of VEGF in papillary thyroid cancer. We hypothesized that increased expression of VEGF would be associated with either an increased risk of recurrence or a decreased recurrence-free survival in papillary thyroid cancer.
METHODS: Immunohistochemistry was used to detect VEGF expression in archival paraffin-embedded surgical thyroid specimens from 96 subjects with papillary thyroid cancer.
RESULTS: VEGF expression was detected in 98% (94/96) of the samples, predominantly of slight-to-moderate intensity in the majority of malignant cells. However, the specific finding of a diffuse pattern of intense immunostaining for VEGF was detected significantly more often than less intense, patchy immunostaining patterns in subjects with distant metastasis at diagnosis (63% versus 15%, P =.005), local recurrence (58% versus 13%, P =.001), and distant recurrence (83% versus 14%, P =.001). Furthermore, this specific pattern of diffuse, intense VEGF expression was associated with a significantly shorter recurrence-free survival than other staining patterns (P =.007).
CONCLUSIONS: These data demonstrate that the immunohistochemical pattern of VEGF staining in the initial surgical specimen is strongly associated with the incidence of local and distant metastasis in papillary thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11331447     DOI: 10.1067/msy.2001.112592

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  35 in total

1.  Preoperative determination of serum thyroglobulin to identify patients with differentiated thyroid cancer who may present recurrence without increased thyroglobulin.

Authors:  B Gibelli; P Tredici; C De Cicco; L Bodei; M T Sandri; G Renne; R Bruschini; N Tradati
Journal:  Acta Otorhinolaryngol Ital       Date:  2005-04       Impact factor: 2.124

2.  Angiogenic response to bioactive glass promotes bone healing in an irradiated calvarial defect.

Authors:  Ann Leu; Susanne M Stieger; Paul Dayton; Katherine W Ferrara; J Kent Leach
Journal:  Tissue Eng Part A       Date:  2009-04       Impact factor: 3.845

3.  Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer.

Authors:  Eric J Sherman; Lara A Dunn; Heiko Schöder; Alan L Ho; Shrujal S Baxi; Ronald A Ghossein; Sofia S Haque; Cami Sima; Robert Michael Tuttle; David G Pfister
Journal:  Cancer       Date:  2019-06-07       Impact factor: 6.860

Review 4.  Evolving molecularly targeted therapies for advanced-stage thyroid cancers.

Authors:  Keith C Bible; Mabel Ryder
Journal:  Nat Rev Clin Oncol       Date:  2016-03-01       Impact factor: 66.675

5.  Thyroid cancer: pathogenesis and targeted therapy.

Authors:  David A Liebner; Manisha H Shah
Journal:  Ther Adv Endocrinol Metab       Date:  2011-10       Impact factor: 3.565

Review 6.  Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions.

Authors:  R Dadu; M E Cabanillas
Journal:  Minerva Endocrinol       Date:  2012-12       Impact factor: 2.184

7.  Functional thyrotropin receptor attenuates malignant phenotype of follicular thyroid cancer cells.

Authors:  S Hoffmann; K Maschuw; I Hassan; A Wunderlich; S Lingelbach; A Ramaswamy; L C Hofbauer; A Zielke
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

Review 8.  Novel treatments for anaplastic thyroid carcinoma.

Authors:  Silvia Martina Ferrari; Giusy Elia; Francesca Ragusa; Ilaria Ruffilli; Concettina La Motta; Sabrina Rosaria Paparo; Armando Patrizio; Roberto Vita; Salvatore Benvenga; Gabriele Materazzi; Poupak Fallahi; Alessandro Antonelli
Journal:  Gland Surg       Date:  2020-01

9.  Nitrotyrosine, inducible nitric oxide synthase (iNOS), and endothelial nitric oxide synthase (eNOS) are increased in thyroid tumors from children and adolescents.

Authors:  A Patel; C Fenton; R Terrell; P A Powers; C Dinauer; R M Tuttle; G L Francis
Journal:  J Endocrinol Invest       Date:  2002-09       Impact factor: 4.256

10.  The comparison of serum vascular endothelial growth factor levels between patients with metastatic and non-metastatic thyroid cancer, and patients with nontoxic multinodular goiter.

Authors:  Joanna Klubo-Gwiezdzinska; Roman Junik; Ewa Kopczynska; Olga Juraniec; Hanna Kardymowicz
Journal:  Eur J Endocrinol       Date:  2007-10       Impact factor: 6.664

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.